Toledo Community Oncology Program Logo

Member Login Phone: 419-843-6147
Email: info@tcop.info

Trial Search

TCOP conducts a variety of clinical trials every year. In fact, there are over 100 trials running at any given time, each specifically focusing on a particular type of cancer research. To find out if there are current trials running, addressing a specific form of cancer, click on a cancer type in the list below.


  • Brain
    • Glioblastoma
      • A221101
        • A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiform
      • A071101
        • A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND# 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resective Recurrent Glioblastoma Multiforme (GBM)
      • N1174
        • Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab verus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme.
  • Breast
    • Adjuvant
      • NSABP B-47
        • Randomized Phase 3 Trial of Adjuvant Therapy comparing Chemotherapy Alone (Six cycles of Docetaxel Plus Cyclophosphamide or Four cycles of Doxorubicin Plus Cyclophosphamide Followed by Weeekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2 Low Invasive Breast Cancer (CIRB)
      • S1007
        • Phase III, Randomized Clinical trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and HER2 Negative Breast Cancer with Recurrence Score of 25 or less.
    • Breast
      • RTOG-1110
        • Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2 Positive Breast Cancer - A Colloborative Study of RTOG and KROG
      • SCUSF 1102
        • A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
    • Cancer Control
      • HLMCC 0806
        • Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving Neo-Adjuvant Chemotherapy with Trastuzumab (Herceptin)
      • A011104
        • Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
      • E2112
        • A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer (CIRB)
    • Early Stage
      • S1202
        • A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
    • HER2 Negative
      • NSABP B-49
        • A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (CIRB)
    • HER2+
      • NSABP B-43-CC
        • Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2+ Ductal Carcinoma In Situ Resected by Lumpectomy (CIRB)
      • RTOG-1119
        • Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG
      • NSABP B-52
        • A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation (CIRB)
    • Metastatic Breast
      • E2108
        • Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer (CIRB)
    • Node Positive
      • A011202
        • A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (CIRB)
  • Cancer Control
    • Cancer Control
      • PACCT-1 Ancillary
        • Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Tretament (TAILORx Trial)
      • E1Z11
        • A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
  • Gastrointestinal
    • Colon
      • CALGB-80702
        • Phase III Trial of 6 vs. 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
      • S0820
        • Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
    • Gastroesophageal
      • RTOG-1010
        • Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma (CIRB)
      • CALGB-80803
        • Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
      • S1201
        • Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Cancer
    • Hepatocellular
      • E1208
        • Phase III Randomized, double-Blind Trial of Chemoemobolization With or Without Sorafenib in unresectable Hepatocellular Carcinoma in Patients With or Without Vascular Invasion (CIRB)
    • Pancreas
      • RTOG-0848
        • Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancrease Adenocarcinoma (CIRB)
      • E2211
        • A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
      • E2212
        • A Randomized, Double-blinded, Placebo-controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver (CIRB)
  • Genitourinary
    • Prostate
      • RTOG-0534
        • Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy QOL closed 4/11/2012 (CIRB)
      • RTOG-0815
        • A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer----QOL Closed 4/11/2912 (CIRB)
      • RTOG-0924
        • Androgen Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial (CIRB)
      • S1216
        • Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (CIRB)
      • CALGB-70807
        • The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
      • A031201
        • PHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER (CIRB)
    • Renal Cell
      • S0931
        • Phase III Study: Everolimus for Renal Cancer Ensuing Surgical Therapy (CIRB)
      • A031203
        • Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma
    • Transitional Cell
      • CALGB-90601
        • Randomized, Double-Blinded, Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
  • GYN
    • Cervical
      • GOG-0274
        • A Phase III Trial Of Adjuvant Chemotherapy As Primary Treatment For Locally Advanced Cervical Cancer Compared To Chemoradiation Alone: The Outback Trial
    • Ovarian
      • GOG0225
        • Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?
    • Uterine Corpus
      • GOG0238
        • A Randomized Trial of Pelvic Irradiation With Or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus
  • Head and Neck
    • Head/Neck
      • RTOG-0920
        • A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer (CIRB)
      • E1311
        • A randomized phase II trial of Afatinib (BIBW2992) as adjuvant therapy following chemoradiation in patients with head and neck squamous cell carcinoma at high risk of recurrence
    • Nasopharyngeal
      • NRG-HN001
        • RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID (DNA) (CIRB)
  • Hematology
    • Anemia
      • E2905
        • Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlamid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate -1 Risk MDS and Symptomatic Anemia (CIRB)
    • B-Cell Lymphoma
      • E1412
        • Randomized Phase II Study of Lenalidomide R-CHOP (R2CHOP) vs R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
    • Chronic Lymphocytic Leukemia
      • A041202
        • A Randomized Phase III Study Of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL) (CIRB)
      • E1912
        • A Randomized Phase III Study of PCI-32765-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) (CIRB)
    • Follicular Lymphoma
      • E2408
        • A 3-Arm Randomized Phase 2 Trial Of Bendamustine-Rituximab Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
      • CALGB-50904
        • Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lympoma
      • E2408-QOL
        • A 3-Arm Randomized Phase 2 Trial Of Bendamustine-Rituximab Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
    • Hematology
      • S1117 - (Suspended)
        • Randomized Phase II Study of Azacitidine in Combinatino with Lenalidomide vs. Azacitine Alone vs. Azacitidine in Combination with Vorinastat for Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia
    • Hodgkins
      • CALGB-50801
        • A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
    • Leukemia
      • E1910
        • A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults (CIRB)
    • Multiple Myeloma
      • S1211
        • A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
      • OSU 10155
        • Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis
      • S1304
        • A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease.
  • Lung
    • Lung
      • S1400
        • PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCER (CIRB)
    • Non-Small Cell
      • S0819 - (Suspended)
        • Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (CIRB)
      • E5508
        • Randomized Phase III Study of Maintenance therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer (CIRB)
      • E6508
        • Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
    • Small Cell
      • RTOG-0937
        • Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer ((ED-SCLC)
  • Melanoma
    • Melanoma
      • E1609-QOL
        • Phase III Study of Adjuvant Ipilimumab anti-CTLA4 Therapy vs. High Dose Interferon Alpha 2B for Resected High-Risk Melanoma
      • E3611
        • A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-α in Advanced Melanoma
    • Unresectable
      • E3612
        • A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
  • Pharmaceutical - Limited Sites.
    • Breast
      • 20130110
        • Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients
    • Colorectal
      • BTCL-PGG-CRC-1031
        • Phase III Open-Label Randomzied, Multicenter Study of Imprime PGG in Combination with Erbitux in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    • Lung
      • MO22097
        • Open-Label, Randomized, Phase IIIB Trial Evaluating the Efficacy and Safety of Standard of Care +/- continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer After First-Line Treatment with Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
    • Metastatic Breast
      • PrE0102
        • Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
      • ABI-007-MBC-001
        • A Phase 2/3, Multi-Center, Open-Label, Randomized Study Of Weekly Nab®-Paclitaxel In Combination With Gemcitabine Or Carboplatin, Compared To Gemcitabine/Carboplatin, As First Line Treatment In Subjects With Er, Pgr, And Her2 Negative (Triple Negative) Metastatic Breast Cancer
    • Metastatic Colorectal
      • OBS13597-OZONE
        • Prospective International Observational Cohort Non-Comparative Study Describing The Safety And Effectiveness Of ZALTRAP® administered In Combination With FOLFIRI For The Treatment Of Patients With Metastatic Colorectal Cancer In Current Clinical Practice: A Post-Authorisation Safety Study (PASS)
    • Non-Hodgkins Lymphoma
      • PIX306
        • Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine and Rituximab in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma who have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
      • PrE0401
        • Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin’s Lymphoma
  • Unspecified
    • Carcinoid Tumor
      • A021202
        • Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
    • Metastatic
      • RTOG-0631
        • Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
    • Patient Satisaction Survey
      • N0392
        • Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials (1 page information consent approved IRB 11/14/07)